6-Mercaptopurine (6-MP) is an antimetabolite. The drug inhibits DNA synthesis of cells by acting as a false analog of purines. 6-MP displays a cytostatic and immunosuppressive activity. The studies carried out so far focus mostly on recognizing the clinical effectiveness of 6-MP, particularly in treating autoimmune diseases, whereas its effect on the osseous tissue still remains unknown. We examined the effect of 6-MP on the osseous system in rats after a 4-week period of its administration by analyzing histomorphometric parameters and bone mass, mineral and calcium content. We also tested the reversal of the above changes after the lapse of 4 week-period during which 6-MP was not administered. Male Wistar rats were divided into 6 groups, each group was composed of 8 animals. Treatment of 6-MP started on day 2 of the experiment, and the drug was administered for 28 days, i.e. between day 2 and 29 in all groups examined. Changes in the histomorphometric parameters were examined in 3 groups 4 weeks after the first 6-MP or 0.9% NaCl administration: I - control group (0.9% NaCl solution), II - 6MP group (6-MP at the dose of 2.5 mg/kg po), III - 6-MP group (6-MP at the dose of 5 mg/kg po). Reversal of the changes was examined 8 weeks after the first 6-MP or 0.9% NaCl administration in 3 groups: IV - control group (0.9% NaCl solution), V - 6-MP group (6-MP at the dose of 2.5 mg/kg po), VI - 6-MP group (6MP at the dose of 5 mg/kg po). We demonstrated that 6-MP administered orally at a dose of 2.5 mg/kg po or at a dose of 5 mg/kg po for the period of 4 weeks inhibited the synthesis and mineralization of the osseous tissue by causing a disorder in histomorphometric parameters, which were not totally reversed after 4 weeks. 6-MP administered at a dose of 5 mg/kg also caused a reduction of mineral and calcium content, mostly in the cancellous bone, which returned to normal after 4 weeks.

Download full-text PDF

Source

Publication Analysis

Top Keywords

dose mg/kg
28
6-mp
17
histomorphometric parameters
16
09% nacl
16
6-mp administered
12
weeks 6-mp
12
group 6-mp
12
6-mp dose
12
6-mp group
12
6-mercaptopurine 6-mp
8

Similar Publications

∆-Tetrahydrocannabinol Increases Growth Factor Release by Cultured Adipose Stem Cells and Adipose Tissue in vivo.

Tissue Eng Regen Med

January 2025

Department of Plastic Surgery, Hand Surgery-Burn Center, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.

Background: Because of its biocompatibility and its soft and dynamic nature, the grafting of adipose tissue is regarded an ideal technique for soft-tissue repair. The adipose stem cells (ASCs) contribute significantly to the regenerative potential of adipose tissue, because they can differentiate into adipocytes and release growth factors for tissue repair and neovascularization to facilitate tissue survival. The present study tested the effect of administering a chronic low dose of ∆-tetrahydrocannabinol (THC) on these regenerative properties, in vitro and in vivo.

View Article and Find Full Text PDF

Genital tract infections are common causes of male infertility, and most of diagnosed men are asymptomatic. This study examined the effect of gallic acid (GA) against lipopolysaccharide (LPS)-induced testicular inflammation. Thirty-two Spraque Dawley, 2.

View Article and Find Full Text PDF

Background: Surgical intervention is critical in the treatment of hip developmental dysplasia in children. Perioperative analgesia, usually based on high opioid dosages, is frequently used in these patients. In some circumstances, regional anesthetic procedures such as caudal block and lumbar plexus block have also been used.

View Article and Find Full Text PDF

Sarcopenia, the pathological age-related loss of muscle mass and strength, contributes to physical decline, frailty, and diminished healthspan. The impact of sarcopenia is expected to rise as the aging population grows, and treatments remain limited. Therefore, novel approaches for enhancing physical function and strength in older adults are desperately needed.

View Article and Find Full Text PDF

The approved intravenous adeno-associated virus (AAV) therapies are limited by the widespread prevalence of pre-existing anti-AAV antibodies in the general population, which are known to restrict patients' ability to receive gene therapy and limit transfection efficacy in vivo. To address this challenge, we have developed a novel recombinant human immunoglobulin G degrading enzyme KJ103, characterized by low immunogenicity and clinical value for the elimination of anti-AAV antibodies in gene transfer. Herein, we conducted two randomized, blinded, placebo-controlled, single ascending dose Phase I studies in China and New Zealand, to evaluate the pharmacokinetics, pharmacodynamics, safety and immunogenicity of KJ103 in healthy volunteers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!